Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
Source : https://www.sciencedirect.com/science/article/pii/S0145212623000590?via=ihub
Patients preferred ide-cel to other treatments for efficacy and side effect profile. * Despite impactful side effects, patients still considered ide-cel advantageous. * Quality-of-life improved 6 months after treatment and...
Conclusions: Longitudinal analysis of patient experiences showed sustained benefits and preference for ide-cel up to 24 months after treatment.
The core symptom in multiple myeloma patients undergoing chemotherapy: a network analysis - Supportive Care in Cancer
Source : https://link.springer.com/article/10.1007/s00520-023-07759-7
Background During chemotherapy for multiple myeloma, symptoms include those related to the disease, as well as adverse effects of the treatment. Few studies have explored the relationships between these symptoms....
Implications for Practice: Nurses and health care teams should be a priority to intervene in the worrying for chemotherapy-treated multiple myeloma patients to maximize the effectiveness of an intervention. Except, nausea and vomiting should be managed together in a clinical setting.
Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients - BMC Cancer
Source : https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-10824-3
Background Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory multiple myeloma (RRMM), leading to unprecedented responses in this patient population. Idecabtagene vicleucel (ide-cel) has been...
Conclusions: We report one of the first cohorts of RRMM treated with commercial ide-cel. The ORR was 69% and safety profile was manageable, but prolonged hematologic toxicity still represents a major challenge. Responses correlated with in vivo CAR T cell expansion, underlining the need of further research to optimize CAR T...
Daratumumab-lenalidomide and daratumumab-pomalidomide in... : Anti-Cancer Drugs
Source : https://journals.lww.com/anti-cancerdrugs/Abstract/9900/Daratumumab_lenalidomide_and.186.aspx
utive multiple myeloma patients who received daratumumab at Mayo Clinic between January 2015 and April 2019. We excluded patients who received daratumumab in the first line, received more than four...
Conclusions/Relevance: Our study shows combining daratumumab with lenalidomide in patients with prior lenalidomide use is a viable and effective treatment option.
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies
Source : https://www.sciencedirect.com/science/article/abs/pii/S0037196323000197?via=ihub
The main toxicities of CAR T-cell therapy are cytokine release syndrome (CRS), the neurological syndrome called Immune Effector Cell (IEC) Associated Neurologic Syndrome (ICANS), and cytopenias [1], [2], [3]. Hypogammaglobulinemia...
Conclusions/Relevance: The goal of this review is to present the infectious complications of CAR T-cell therapy, explain their temporal course and risk factors, and provide recommendations for their prevention, diagnosis, and management.